**Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer**

Eben L. Rosenthal1, Lindsay S. Moore2, Kiranya Tipirneni3, Esther de Boer4, Todd M. Stevens5, Yolanda E. Hartman2, William R. Carroll2, Kurt R. Zinn6, Jason M. Warram2

1Department of Otolaryngology, Stanford University

2Department of Otolaryngology, University of Alabama at Birmingham

3Department of Surgery, University of Alabama at Birmingham

4Department of Surgery, University Medical Center Groningen University of Groningen, Groningen, The Netherlands

5Department of Pathology, University of Alabama at Birmingham

6Department of Radiology, University of Alabama at Birmingham

**SUPPLIMENTAL MATERIAL**

****

**Supplementary Figure 1** Fluorescence acquisitions of grossed lymph nodes. Closed-field images of whole dissected lymph nodes and fluorescence slide scanner images of histological section with adjacent histological staining of representative true positive, false positive, and true negative for (**a**) cohort 1 – 2.5mg/m2 dose group, (**b**) cohort 2 – 25mg/m2 dose group, and (**c**) cohort 2 – 62.5mg/m2 dose group. Color bar represents closed-field acquisition threshold matching for each cohort shown.



**Supplementary Figure 2** Analysis of false positive fluorescence. (**a**) Representative fluorescence slide scan of tissue-mounted section from cohort 3 with (**b**) adjacent histology. Inset image displays CD68 positive cells with adjacent histology highlighting areas of prominent sinus histiocytosis.

**Supplementary video 1** Representative video is shown of open-field imaging during intraoperative neck dissection from the 25mg/m2 dose cohort.